EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Efficacy and safety of mycophenolate mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): a multicenter, phase II clinical trial

Nut Koonrungsesomboon, Pimpisa Teeyakasem, Nahathai Dukaew, Nutnicha Sirikaew, Patcharawadee Thongkumkoon, Petlada Yongpitakwattana, Viraporn Thepbundit, Parunya Chaiyawat, Jeerawan Klangjorhor, Chotiwit Sakuludomkan, Chaiyut Charoentum, Busyamas Chewaskuyong und 5 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02877-0 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Nut Koonrungsesomboon und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. nkoonrung@gmail.com. Hauptthemen laut MEDLINE: Bone Neoplasms, Mycophenolic Acid, Osteosarcoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Science and Technology Development Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Osteosarcoma is a prevalent and aggressive bone malignancy primarily affecting young adults. Despite advances in standard treatment, the 5-year survival rate remains low, highlighting the need for new chemotherapy options. Mycophenolate mofetil, an immunosuppressant used post-transplant, has shown promising preclinical anticancer effects in osteosarcoma, warranting further investigation for potential repurpose in humans. METHODS: We conducted this proof-of-concept phase II clinical trial to assess the efficacy and safety of mycophenolate mofetil in high-grade locally advanced or metastatic osteosarcoma. Patients received 3-5 g/day mycophenolate mofetil for four 28-day cycles or until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) at 16 weeks. Secondary endpoints included overall survival (OS), overall response rate, safety, pharmacokinetics, pain score, and quality of life. RESULTS: Fifteen patients were enrolled. Due to intolerable toxicity at higher doses, most patients received 3 g/day of mycophenolate mofetil. At 16 weeks, the PFS rate was 40%, with only one patient (6.7%) achieving stable disease. Median PFS and OS were 70 and 301 days, respectively. The most common grade 3-4 adverse events were anemia and fatigue, each occurring in 20% of patients. Pharmacokinetic analysis revealed high interindividual variability. CONCLUSION: Although mycophenolate mofetil at 3 g/day was well tolerated, it did not meet expectations for anticancer efficacy in patients with high-grade locally advanced or metastatic osteosarcoma. This study should be considered a negative trial. Further research is needed to explore the therapeutic role of mycophenolate mofetil through alternative strategies or identify more effective interventions for osteosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsMycophenolic AcidOsteosarcomaAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultNeoplasm MetastasisProgression-Free SurvivalProof of Concept StudyQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

AnticancerClinical trialMycophenolate mofetilMycophenolic acidOsteosarcoma

Substanzen

Mycophenolic Acid

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. nkoonrung@gmail.com.
  • Center of Multidisciplinary Technologies for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. nkoonrung@gmail.com.
  • Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. nkoonrung@gmail.com.
  • Center of Multidisciplinary Technologies for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
  • Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
  • Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.

Förderung

  • National Science and Technology Development Agency

Zitieren

APA

Koonrungsesomboon, N., Teeyakasem, P., Dukaew, N., Sirikaew, N., Thongkumkoon, P., Yongpitakwattana, P., Thepbundit, V., Chaiyawat, P., Klangjorhor, J., Sakuludomkan, C., Charoentum, C., Chewaskuyong, B., Sathitsamitphong, L., Kiatisevi, P., Sunpaweravong, P., Sathitruangsak, C., & Pruksakorn, D. (2025). Efficacy and safety of mycophenolate mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): a multicenter, phase II clinical trial. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02877-0

Vancouver

Koonrungsesomboon N, Teeyakasem P, Dukaew N, Sirikaew N, Thongkumkoon P, Yongpitakwattana P, et al. Efficacy and safety of mycophenolate mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): a multicenter, phase II clinical trial. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02877-0

BibTeX
@article{Koonrungsesomboon2025,
  author = {Koonrungsesomboon, Nut and Teeyakasem, Pimpisa and Dukaew, Nahathai and Sirikaew, Nutnicha and Thongkumkoon, Patcharawadee and Yongpitakwattana, Petlada and Thepbundit, Viraporn and Chaiyawat, Parunya and Klangjorhor, Jeerawan and Sakuludomkan, Chotiwit and Charoentum, Chaiyut and Chewaskuyong, Busyamas and Sathitsamitphong, Lalita and Kiatisevi, Piya and Sunpaweravong, Patrapim and Sathitruangsak, Chirawadee and Pruksakorn, Dumnoensun},
  title = {Efficacy and safety of mycophenolate mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): a multicenter, phase II clinical trial},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02877-0}
}
Kostenlos starten →